Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Share:
Related MRK
Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story
Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni
Merck presents data on two HCV Phase 2s at Liver Meeting (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

DateFirmActionFromTo
Mar 2015Leerink SwannMaintainsMarket Perform
Mar 2015JefferiesMaintainsHold
Feb 2015JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...